Skull Base Osteomyelitis: A 5‐Year Review and Prognostic Outcome in a Single Tertiary Institution

Abstract

AbstractObjectiveThe primary objective of this study is to review the clinical parameters associated with skull base osteomyelitis (SBO), with a secondary aim of studying their association with patient outcomes 1 and 6 months after treatment initiation.Study DesignThis is a single‐center restrospective observational study.SettingThe study was conducted from January 2018 to December 2022 at the University Malaya Medical Center in Kuala Lumpur.MethodsPatients aged over 15 years with a diagnosis of SBO were included in the study. Clinical parameters, investigations, and follow‐up records were recorded. The disease outcomes were analyzed at 1 and 6 months after treatment initiation using multivariable analyses.ResultsThe study identified 31 patients with SBO, the majority of whom were elderly males with comorbidities such as diabetes and hypertension. Otalgia and otorrhea were the most common symptoms, and computed tomography scans were used for diagnosis. Pseudomonas aeruginosa was the most commonly identified pathogen, and intravenous broad‐spectrum antimicrobials were used to treat all patients. Surgical intervention was required for 25% of patients, and underlying ischemic heart disease, anemia, and single nerve palsy were significantly associated with an unfavorable prognosis. Patients with higher body mass index and elevated C‐reactive protein showed poorer outcomes after 1 and 6 months of treatment, respectively.ConclusionEarly recognition, prompt treatment, better control of comorbidities, nutrition, and monitoring can improve SBO outcomes and reduce complications. Therefore, as the prevalence of SBO increases, diagnostic criteria or management guidelines should be established to guide the best clinical practice.